Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.59 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.54 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.54 |
| ▸ | SLC5A2 | P31639 | 2/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.49 |
| ▸ | IDO1 | P14902 | 2/20 | 0.47 |
| ▸ | DAO | P14920 | 2/20 | 0.46 |
| ▸ | FDPS | P14324 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
| ▸ | HTR2B | P41595 | 1/20 | 0.46 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.45 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.44 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.44 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30528053 | 1.00 | TAAR1 (0.59) | TAAR1CYP4F2CYP4A11SLC5A2HRH3 | |
| Dimethylamine SCHEMBL9872133 | 0.94 | TAAR1 (0.53) | TAAR1CYP4F2CYP4A11SLC5A2HRH3 | |
| SCHEMBL5303210 | 0.94 | TAAR1 (0.57) | TAAR1CYP4F2CYP4A11SLC5A2HRH3 | |
| SCHEMBL3504070 | 0.92 | TAAR1 (0.55) | TAAR1CYP4F2CYP4A11SLC5A2HRH3 | |
| SCHEMBL12821195 | 0.92 | TAAR1 (0.55) | TAAR1CYP4F2CYP4A11SLC5A2HRH3 | |
| Pyrazine SCHEMBL27797318 | 0.91 | TAAR1 (0.50) | TAAR1CYP4F2CYP4A11SLC5A2HRH3 | |
| Butyl Alcohol SCHEMBL27857142 | 0.89 | TAAR1 (0.52) | TAAR1CYP4F2CYP4A11SLC5A2HRH3 | |
| SCHEMBL30203725 | 0.87 | TAAR1 (0.63) | TAAR1CYP4F2CYP4A11SLC5A2HRH3 | |
| SCHEMBL296315 | 0.87 | TAAR1 (0.63) | TAAR1CYP4F2CYP4A11SLC5A2HRH3 | |
| SCHEMBL8092500 | 0.87 | TAAR1 (0.68) | TAAR1SLC5A2HRH3IDO1DAO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 133 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023179870-A1 | ETHYL 4-OXOPENTANOATE FOR REDUCING ODORS | SYMRISE AG (DE) | 2023-09-28 | — | — | WO | claimed |
| EP-4680184-A1 | HIGH PERFORMANCE FRAGRANCE COMPOSITIONS FOR RINSE-OFF CONDITIONER | International Flavors & Fragrances Inc. (US) | 2026-01-21 | — | — | EP | disclosed |
| WO-2024192221-A1 | HIGH PERFORMANCE FRAGRANCE COMPOSITIONS FOR RINSE-OFF CONDITIONER | INTERNATIONAL FLAVORS & FRAGRANCES INC. (US) | 2024-09-19 | — | — | WO | disclosed |
| WO-2023179870-A1 | ETHYL 4-OXOPENTANOATE FOR REDUCING ODORS | SYMRISE AG (DE) | 2023-09-28 | — | — | WO | disclosed |
| EP-4076007-A1 | DODECANDIEN-1-OL AND DODECEN-1-OL OR MIXTURES THEREOF AS AROMA CHEMICALS | BASF SE (DE) | 2022-10-26 | — | — | EP | disclosed |
| EP-3256451-B1 | IMIDAZOLYL TRICYCLIC ENONES AS ANTIOXIDANT INFLAMMATION MODULATORS | REATA PHARMACEUTICALS INC (US) | 2021-10-20 | — | — | EP | disclosed |
| US-20190002454-A1 | NRF2 Regulators | GLAXOSMITHKLINE IP DEV LTD (GB) | 2019-01-03 | — | — | US | disclosed |
| US-20190002454-A1 | NRF2 Regulators | GLAXOSMITHKLINE IP DEV LTD (GB) | 2019-01-03 | — | — | US | disclosed |
| US-10144731-B2 | Nrf2 regulators | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-12-04 | — | — | US | disclosed |
| CN-108139401-A | COMPOSITIONS AND METHODS FOR DIAGNOSING LYME DISEASE AND FOR PREDICTING LYME DISEASE SPIROCHETE ELIMINATION AFTER TREATMENT | 凯杰科技有限公司 | 2018-06-08 | — | — | CN | disclosed |
| US-5545638-A | USING A 3-(TETRAHYDROPYRID-3-YL-) SUBSTITUTED (OXA- OR THIA-)DIAZOLE COMPOUND | NOVO NORDISK A/S (DK) | 1996-08-13 | — | — | US | disclosed |
| US-5521282-A | FROM 4-/2,3-EPOXYPROPOXY/-2,2,6,6-TETRAMETHYLPIPERIDINE | CIBA-GEIGY CORPORATION (US) | 1996-05-28 | — | — | US | disclosed |
| WO-1996014066-A1 | A METHOD OF TREATING URINARY BLADDER DYSFUNCTIONS | NOVO NORDISK A/S (DK) | 1996-05-17 | — | — | WO | disclosed |
| EP-0687265-A1 | HETEROCYCLIC COMPOUNDS AND THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 1995-12-20 | — | — | EP | disclosed |
| WO-1995017185-A1 | A METHOD OF TREATING GASTROINTESTINAL MOTILITY DISORDERS | NOVO NORDISK A/S (DK) | 1995-06-29 | — | — | WO | disclosed |
| WO-1995005174-A1 | ANTIPSYCHOTIC METHOD | NOVO NORDISK A/S (DK) | 1995-02-23 | — | — | WO | disclosed |
| EP-0634449-A2 | Polyether with sterically hindered amine side chains as stabilizing agents | CIBA-GEIGY AG (CH) | 1995-01-18 | — | — | EP | disclosed |
| WO-1994020495-A1 | HETEROCYCLIC COMPOUNDS AND THEIR PREPARATION AND USE | NOVO NORDISK A/S (DK) | 1994-09-15 | — | — | WO | disclosed |
| US-4590291-A | Thrombin inhibitory new dihydroxybenzene ether derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 1986-05-20 | — | — | US | disclosed |
| EP-0068250-A1 | Dioxybenzene ether derivatives, pharmaceutical compositions containing them, process for the preparation thereof and their use | BAYER AG (DE) | 1983-01-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190002454-A1 | NRF2 Regulators | NFE2L2, KEAP1, NQO1 | TAAR1 2665/4885CYP4F2 100/4885CYP4A11 123/4885 |
| US-10144731-B2 | Nrf2 regulators | NFE2L2, KEAP1, NQO1 | TAAR1 2665/4885CYP4F2 100/4885CYP4A11 123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.